| DNA-repair defects and olaparib in metastatic prostate cancer J Mateo, S Carreira, S Sandhu, S Miranda, H Mossop, R Perez-Lopez, ... New England Journal of Medicine 373 (18), 1697-1708, 2015 | 2291 | 2015 |
| Long-term follow-up of a large active surveillance cohort of patients with prostate cancer L Klotz, D Vesprini, P Sethukavalan, V Jethava, L Zhang, S Jain, ... Journal of Clinical Oncology, JCO. 33(3) 272-277, 2015 | 1331 | 2015 |
| Gold nanoparticles as novel agents for cancer therapy S Jain, DG Hirst, JM O'sullivan The British journal of radiology, 2012 | 1262 | 2012 |
| Olaparib in patients with metastatic castration-resistant prostate cancer with DNA repair gene aberrations (TOPARP-B): a multicentre, open-label, randomised, phase 2 trial J Mateo, N Porta, D Bianchini, U McGovern, T Elliott, R Jones, I Syndikus, ... The Lancet Oncology 21 (1), 162-174, 2020 | 574 | 2020 |
| Cell-specific radiosensitization by gold nanoparticles at megavoltage radiation energies S Jain, JA Coulter, AR Hounsell, KT Butterworth, SJ McMahon, ... International Journal of Radiation Oncology* Biology* Physics 79 (2), 531-539, 2011 | 555 | 2011 |
| Biological consequences of nanoscale energy deposition near irradiated heavy atom nanoparticles SJ McMahon, WB Hyland, MF Muir, JA Coulter, S Jain, KT Butterworth, ... Scientific reports 1 (1), 18, 2011 | 461 | 2011 |
| Intensity-modulated fractionated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): acute toxicity findings from an international, randomised … DH Brand, AC Tree, P Ostler, H van der Voet, A Loblaw, W Chu, D Ford, ... The Lancet Oncology 20 (11), 1531-1543, 2019 | 444 | 2019 |
| Active surveillance for the management of localized prostate cancer (Cancer Care Ontario Guideline): American Society of Clinical Oncology clinical practice guideline endorsement RC Chen, RB Rumble, DA Loblaw, A Finelli, B Ehdaie, MR Cooperberg, ... Journal of Clinical Oncology 34 (18), 2182-2190, 2016 | 411 | 2016 |
| Evaluation of cytotoxicity and radiation enhancement using 1.9 nm gold particles: potential application for cancer therapy KT Butterworth, JA Coulter, S Jain, J Forker, SJ McMahon, G Schettino, ... Nanotechnology 21 (29), 295101, 2010 | 306 | 2010 |
| Drug related medical emergencies in the elderly: role of adverse drug reactions and non-compliance S Malhotra, RS Karan, P Pandhi, S Jain Postgraduate medical journal 77 (913), 703-707, 2001 | 280 | 2001 |
| UK consensus on normal tissue dose constraints for stereotactic radiotherapy GG Hanna, L Murray, R Patel, S Jain, KL Aitken, KN Franks, N Van As, ... Clinical Oncology 30 (1), 5-14, 2018 | 248 | 2018 |
| Nanodosimetric effects of gold nanoparticles in megavoltage radiation therapy SJ McMahon, WB Hyland, MF Muir, JA Coulter, S Jain, KT Butterworth, ... Radiotherapy and Oncology 100 (3), 412-416, 2011 | 238 | 2011 |
| Genomics of lethal prostate cancer at diagnosis and castration resistance J Mateo, G Seed, C Bertan, P Rescigno, D Dolling, I Figueiredo, ... The Journal of clinical investigation 130 (4), 1743-1751, 2020 | 235 | 2020 |
| Radiotherapy in the presence of contrast agents: a general figure of merit and its application to gold nanoparticles SJ McMahon, MH Mendenhall, S Jain, F Currell Physics in Medicine & Biology 53 (20), 5635, 2008 | 231 | 2008 |
| Cell type-dependent uptake, localization, and cytotoxicity of 1.9 nm gold nanoparticles JA Coulter, S Jain, KT Butterworth, LE Taggart, GR Dickson, SJ McMahon, ... International journal of nanomedicine, 2673-2685, 2012 | 218 | 2012 |
| Active surveillance for intermediate risk prostate cancer: survival outcomes in the Sunnybrook experience HB Musunuru, T Yamamoto, L Klotz, G Ghanem, A Mamedov, ... The Journal of urology 196 (6), 1651-1658, 2016 | 207 | 2016 |
| Prostate stereotactic ablative body radiotherapy using a standard linear accelerator: toxicity, biochemical, and pathological outcomes A Loblaw, P Cheung, L D’Alimonte, A Deabreu, A Mamedov, L Zhang, ... Radiotherapy and Oncology 107 (2), 153-158, 2013 | 182 | 2013 |
| Intensity-modulated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): 2-year toxicity results from an open-label, randomised, phase 3, non … AC Tree, P Ostler, H van der Voet, W Chu, A Loblaw, D Ford, S Tolan, ... The Lancet Oncology 23 (10), 1308-1320, 2022 | 160 | 2022 |
| Optimum imaging strategies for advanced prostate cancer: ASCO guideline EJ Trabulsi, RB Rumble, H Jadvar, T Hope, M Pomper, B Turkbey, ... Journal of Clinical Oncology 38 (17), 1963-1996, 2020 | 157 | 2020 |
| Benefits and risks of primary treatments for high-risk localized and locally advanced prostate cancer: an international multidisciplinary systematic review L Moris, MG Cumberbatch, T Van den Broeck, G Gandaglia, N Fossati, ... European urology 77 (5), 614-627, 2020 | 147 | 2020 |
Joe M. O'SullivanProfessor of Radiation Oncology., Queen's University Belfast在 qub.ac.uk 的电子邮件经过验证
